The numbers are not abstract. Between 2025 and 2030, branded pharmaceutical products generating roughly $400 billion in annual global revenue […]
Build Your Drug Portfolio’s Moat Before the $400 Billion Patent Cliff Swallows It Read Post »
Full drug development — from first synthesis of a new chemical entity to FDA approval — costs, on average, $2.6
Cut Drug R&D Costs by 90%: The 505(b)(2) Playbook the Big Pharma Textbook Ignores Read Post »
The FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, is the primary trade ledger
Profit from the Patent Cliff: ANDA Filing Trends Hidden Inside the FDA Orange Book Read Post »
The Food and Drug Administration (FDA) Orange Book is the primary financial barrier between a blockbuster drug and its generic
Own the Market: How Brand Companies Strategically List Patents in the FDA Orange Book Read Post »
The pharmaceutical market operates as a system of time-limited monopolies where the legal strength of a patent portfolio dictates the
Own the Generic Entry Timeline: From Orange Book Listing to At-Risk Launch Read Post »
The pharmaceutical industry faces a financial contraction of historic proportions. Between 2025 and 2030, $300 billion in annual prescription drug
The $400 Billion Revenue Precipice The biopharmaceutical sector is entering a period of revenue contraction that threatens the financial stability
From Pill to Platform: The Pre-LOE Device Playbook. Read Post »
The global pharmaceutical industry is currently navigating a pivotal transition characterized by a monumental wave of patent expirations that will
The contemporary pharmaceutical landscape is defined by a paradigm shift in lifecycle management (LCM), moving beyond traditional defensive tactics toward
How Formulation Vendors Can Turn Loss of Exclusivity Into a 24-Month Sales Window Read Post »
Get fresh news and insights, drug patent expirations & more…
